Altimmune, Inc. (ALT)
Upgrades & Downgrades
Latest ALT news
7 Small-Cap Stocks with Big Growth Potential in 2023
10 January 2023
Some of the greatest opportunities can be found in these small-cap stocks to buy. For one, a good number of small-cap stocks are severely undervalued.
Altimmune Stock Skyrockets on NAFLD Drug Trial Data
21 December 2022
Altimmune Inc (NASDAQ:ALT) and SINTX Technologies Inc (NASDAQ:SINT) are trending today.
The 7 Hottest Biotech Stocks to Own in 2023 and Beyond
18 December 2022
Some of the hottest biotech stocks are safe and recession-proof. After all, we can't stop people from aging – at least, not yet.
Altimmune Appears To Have A Winner, But Will The Market Believe?
2 December 2022
On September 14, shares plummeted 27% on topline results from a Phase 1 study of pemvidutide. Reductions in liver fat appear to be substantially better than that of the two leading drug candidates for...
Altimmune to Participate at Two Upcoming Investor Conferences
22 November 2022
GAITHERSBURG, Md., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company's management team will parti...
Altimmune, Inc. (ALT) Reports Q3 Loss, Misses Revenue Estimates
10 November 2022
Altimmune, Inc. (ALT) delivered earnings and revenue surprises of 2.04% and 99.89%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Altimmune to Report Third Quarter 2022 Financial Results and Provide Business Update on November 10
3 November 2022
GAITHERSBURG, Md., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its third quarter 2022 financial res...
Altimmune to Present Pemvidutide Clinical Data at the Upcoming AHA Scientific Sessions and AASLD The...
28 October 2022
GAITHERSBURG, Md., Oct. 28, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the Company will be presenting at two upcoming scie...
Altimmune's (ALT) Data From NASH Study Fail to Impress Investors
15 September 2022
Altimmune (ALT) reports positive top-line results from its 12-week phase I study evaluating pemvidutide in patients with non-alcoholic fatty liver disease. The results fail to impress investors.